The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.

Copin, Richard, Baum, Alina, Wloga, Elzbieta, Pascal, Kristen E, Giordano, Stephanie, Fulton, Benjamin O, Zhou, Anbo, Negron, Nicole, Lanza, Kathryn, Chan, Newton, Coppola, Angel, Chiu, Joyce, Ni, Min, Wei, Yi, Atwal, Gurinder S, Hernandez, Annabel Romero, Saotome, Kei, Zhou, Yi, Franklin, Matthew C, Hooper, Andrea T, McCarthy, Shane, Hamon, Sara, Hamilton, Jennifer D, Staples, Hilary M, Alfson, Kendra, Carrion, Ricardo, Ali, Shazia, Norton, Thomas, Somersan-Karakaya, Selin, Sivapalasingam, Sumathi, Herman, Gary A, Weinreich, David M, Lipsich, Leah, Stahl, Neil, Murphy, Andrew J, Yancopoulos, George D, Kyratsous, Christos A (June 2021) The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell. ISSN 0092-8674

[img] PDF
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (6MB)
DOI: 10.1016/j.cell.2021.06.002


Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19. Because rapidly emerging virus mutants are becoming the next major concern in the fight against the global pandemic, it is imperative that these therapeutic treatments provide coverage against circulating variants and do not contribute to development of treatment-induced emergent resistance. To this end, we investigated the sequence diversity of the spike protein and monitored emergence of virus variants in SARS-COV-2 isolates found in COVID-19 patients treated with the two-antibody combination REGEN-COV, as well as in preclinical in vitro studies using single, dual, or triple antibody combinations, and in hamster in vivo studies using REGEN-COV or single monoclonal antibody treatments. Our study demonstrates that the combination of non-competing antibodies in REGEN-COV provides protection against all current SARS-CoV-2 variants of concern/interest and also protects against emergence of new variants and their potential seeding into the population in a clinical setting.

Item Type: Paper
Subjects: diseases & disorders > viral diseases > coronavirus > therapies and treatments > antibody therapy
diseases & disorders > viral diseases > coronavirus > covid 19
bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification > protein types > monoclonal antibody
CSHL Authors:
Communities: CSHL labs > Atwal lab
SWORD Depositor: CSHL Elements
Depositing User: CSHL Elements
Date: 5 June 2021
Date Deposited: 21 Jul 2021 13:43
Last Modified: 21 Jul 2021 13:43
PMCID: PMC8179113

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving